Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Administración General De La Comunidad Autónoma De Euskadi is currently navigating 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners, ensuring that no single examiner is responsible for the company's entire current workload. Furthermore, the portfolio is spread across 2 distinct art units, reflecting a range of technical classifications within their biotechnology filings.
HSU, GRACE CHING serves as the busiest examiner for the portfolio, holding 1 pending action. This figure matches the workload of the other examiner, as the 2 pending actions are split evenly between the 2 distinct examiners. The presence of 2 distinct art units suggests that the company's intellectual property strategy involves different biological or pharmaceutical sub-categories, requiring the legal team to adapt to the specific standards of 2 different administrative groups. This distribution means that the outcome of the 2 pending actions will depend on the unique perspectives of 2 different examiners.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HSU, GRACE CHING | 1 | 73.5% | +31.0% |
| SAMSELL, RILLA MARIE | 1 | 70.8% | +4.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18563554 | 1,2-DIHYDROQUINOLINE-2-ONES FOR THEIR USE IN THE TREATMENT OF LIMB-GIRDLE MUSCULAR DYSTROPHY | HSU, GRACE CHING | 17d overdue |
| 18563568 | THIADIAZOLIDINONES FOR THEIR USE IN THE TREATMENT OF LIMB-GIRDLE MUSCULAR DYSTROPHY | SAMSELL, RILLA MARIE | 5d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18563554 | 1,2-DIHYDROQUINOLINE-2-ONES FOR THEIR USE IN THE TREATMENT OF LIMB-GIRDLE MUSCULAR DYSTROPHY | HSU, GRACE CHING | 17d overdue |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18563554 | 1,2-DIHYDROQUINOLINE-2-ONES FOR THEIR USE IN THE TREATMENT OF LIMB-GIRDLE MUSCULAR DYSTROPHY | HSU, GRACE CHING | 1627 | §103§112 | Non-Final OA | 17d overdue | Pending | Nov 22, 2023 |
| 18563568 | THIADIAZOLIDINONES FOR THEIR USE IN THE TREATMENT OF LIMB-GIRDLE MUSCULAR DYSTROPHY | SAMSELL, RILLA MARIE | 1624 | §103§112 | Final Rejection | 5d overdue | Pending | Nov 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial